Biologic agents for treating ankylosing spondylitis: beyond TNFα antagonists.

[1]  R. Bruckert,et al.  Lack of efficacy of abatacept in axial spondylarthropathies refractory to tumor-necrosis-factor inhibition. , 2012, Joint, bone, spine : revue du rhumatisme.

[2]  P. Goupille,et al.  Optimizing TNFα antagonist therapy in patients with spondyloarthritis: why and how? , 2011, Joint, bone, spine : revue du rhumatisme.

[3]  Y. Shima,et al.  Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis , 2011, Modern rheumatology.

[4]  C. Prati,et al.  Short-term effect of IL-6 inhibition in spondylarthritis. , 2010, Joint, bone, spine : revue du rhumatisme.

[5]  C. Gabay,et al.  Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists. , 2010, Joint, bone, spine : revue du rhumatisme.

[6]  L. Kanz,et al.  Mixed response to tocilizumab for ankylosing spondylitis , 2010, Annals of the rheumatic diseases.

[7]  J. Braun,et al.  Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. , 2010, Arthritis and rheumatism.

[8]  D. Wendling.  Interleukin‐6 as a therapeutic target in spondylarthritis: Comment on the article by Tanaka et al , 2010, Arthritis care & research.

[9]  M. Dougados,et al.  Rituximab in the spondyloarthropathies: data of eight patients followed up in the French Autoimmunity and Rituximab (AIR) registry , 2010, Annals of the rheumatic diseases.

[10]  M. Ann,et al.  リツキシマブ治療を行った難治性成人および若年性皮膚筋炎(DM)と成人多発性筋炎(PM)における臨床的反応の予測因子-RIM試験 , 2010 .

[11]  D. Wendling.  IL-23 and IL-17 in ankylosing spondylitis , 2010, Rheumatology International.

[12]  M. Kawai,et al.  Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. , 2009, Arthritis and rheumatism.

[13]  A. Gottlieb,et al.  Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial , 2009, The Lancet.

[14]  I. Olivieri,et al.  Abatacept in spondyloarthritis refractory to tumour necrosis factor α inhibition , 2008, Annals of the rheumatic diseases.

[15]  B. Giraudeau,et al.  Infliximab for treating axial spondylarthropathy in everyday practice. , 2009, Joint, bone, spine : revue du rhumatisme.

[16]  D. Wendling,et al.  Serum and synovial fluid levels of p40 IL12/23 in spondyloarthropathy patients , 2009, Clinical Rheumatology.

[17]  J. Berthelot,et al.  Six-month response to anti-TNF drugs in axial spondylarthropathy according to the fulfillment or not of New-York criteria for ankylosing spondylitis or French recommendations for anti-TNF use. A "real life" retrospective study on 175 patients. , 2008, Joint, bone, spine : revue du rhumatisme.

[18]  D. Wendling.  Interleukin 23: a key cytokine in chronic inflammatory disease. , 2008, Joint, bone, spine : revue du rhumatisme.

[19]  T. Walley,et al.  Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. , 2007, Health technology assessment.

[20]  D. Wendling,et al.  Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. , 2007, Joint, bone, spine : revue du rhumatisme.

[21]  D. Wendling.  Interleukin-1: a new therapeutic target for ankylosing spondylitis? , 2005, Joint, bone, spine : revue du rhumatisme.

[22]  D. Wendling,et al.  Combination therapy of anti-CD4 and anti-IL6 monoclonal antibodies in a case of severe spondylarthropathy. , 1996, British journal of rheumatology.